Month: February 2026

Press ReleaseNicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual MeetingFebruary 24, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that positive data from the NCX 470 Phase 3 studies were highlighted in 2 podium presentations and a poster at the 2026 American Glaucoma Society (AGS) Annual Meeting (February 19 to February 22), one of the key scientific events in vision research.   Data presented at AGS show that NCX 470, a novel, fast acting molecule, demonstrated best-in-class intraocular pressure (IOP) lowering efficacy of up to 10mmHg from baseline which has met the efficacy requirements for a New Drug Application in the U.S. and China.  ...

Press release                         Regulated information published on February 24, 2026, at 7:00 a.m. CET Strong free cash flow delivery in 2025 in a challenging environment HighlightsUnderlying net sales for the full year 2025 were €4.3 billion, -6.5% organically versus 2024. Soda ash seaborne and Coatis markets were weaker in 2025 while Peroxides and bicarbonate grew year-on-year. Underlying EBITDA was €881 million (-13.4% organically versus 2024), maintaining a strong underlying EBITDA margin of 20.7% despite challenges. Strategic transformation efforts continued to deliver tangible results, with structural cost savings initiatives contributing €101 million in 2025 (€211 million cumulatively). Transformation expenses reduced 2025 EBITDA by €‑27 million and Free Cash Flow1 by €‑71 million. Underlying net profit from continuing...

LIBERTY LAKE, Wash., Feb. 23, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI) (the “Company”), which is innovating new ways for utilities and cities to manage energy and water, today announced the pricing of its private offering of $700.0 million aggregate principal amount of its 0.00% convertible senior notes due 2032 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $600.0 million aggregate principal amount of Notes. The Company also granted the initial purchasers of the Notes an option to purchase, for settlement during a 13-day period beginning on, and including the first day the Notes are issued, an additional $105.0 million...

CHC Navigation Launches RS7 Handheld SLAM Scanner for BIM, Indoor Surveying, and Reality CaptureCHC Navigation Launches RS7 Handheld SLAM Scanner for BIM, Indoor Surveying, and Reality CaptureSHANGHAI, Feb. 23, 2026 (GLOBE NEWSWIRE) — CHC Navigation (CHCNAV) announced the RS7, a new handheld SLAM (Simultaneous Localization and Mapping) scanning solution, unveiled at the 2026 CHCNAV Connect Partner Conference. Built for BIM documentation, indoor surveying, renovation planning, and complex spatial analysis, the CHCNAV RS7 is designed to help professionals capture high density 3D data efficiently and convert it into practical deliverables through CHCNAV’s software and cloud ecosystem. “Customers no longer evaluate hardware in isolation. They expect an end-to-end solution that shortens the path from 3D data capture to deliverables,”...

PERTH, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKRY) (‘Alkane’ or ‘the Company’) is pleased to announce the latest exploration results and drilling for the underground expansion of existing resources at its Tomingley Gold Operations (Tomingley) in New South Wales. Program SummaryExploration drilling at Tomingley has tested a seismic reflector feature beneath the Roswell Deposit and near-mine prospects such as El Paso. Underground drilling at Roswell, outside of grade control, has focused on improving confidence in the Inferred Resources. Roswell underground resources (1.3g/t Au cut-off) are estimated at 5.5Mt grading 2.6g/t Au for an endowment of 476,000 oz Au1. A previous exploration drill hole (RWD061) was extended to 1,392m depth to intersect a seismic reflector identified...

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:TD Cowen 46th Annual Health Care ConferenceDate:Fireside chat:Place:Webcast Link: Monday, March 2, 20262:30 p.m. ETBoston Marriott Copley Place, Boston, Mass.HereJefferies Biotech on the Beach SummitDate:Place: Tuesday, March 10, 20261 Hotel South Beach, Miami Beach, Fla.Barclays 28th Annual Global Healthcare ConferenceDate: Fireside chat: Place: Webcast Link: Wednesday, March 11, 20262:00 p.m. ETLoews Miami Beach, Miami Beach, Fla.HereInvestors interested in arranging a meeting with...

FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Under the partial clinical hold, no new patients will be enrolled in the LINNET study until the partial hold is lifted by the FDA. Current study participants may continue to receive study drug. The FDA’s partial clinical hold was initiated following the Company’s recent notification...